The congress in San Antonio has recently ended. This is probably the most important event dedicated to breast cancer. Are there any interesting, hopeful reports from there?
Yes, there has been a lot of talk about trastuzumab deruxtekan, which is now recommended for the treatment of HER2+ breast cancer. The results of the research were also shown in the so-called HER2-low cancer, which has not yet been considered for treatment with anti-HER2 drugs. The concept of HER2 low cancer has appeared recently, because we have been talking about it for about two years. This is a subtype in which estrogen receptors are present or absent, ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
